Pay in 4 interest-free payments of $5.16 Learn more
Ships within 48 hours · Estimated delivery Aug 30 - Sep 4
doi: 10.1038/s41419-021-03389-1 181 LiakopoulosOJChoiYHHaldenwangPLStrauchJWittwerTDrgeHet al
Saxenda (active ingredient: liraglutide) subcutaneous injection Initial FDA Approval: 2014 (liraglutide approved in 2010) Side Effect Update Date: May 28, 2025 Medication Description: For chronic weight management Updated Side Effects/Safety Information: A new warning section on Severe Gastrointestinal Adverse Reactions. An additional warning about the risk of serious kidney injury caused by dehydration due to gastrointestinal adverse effects like diarrhea and vomiting
The cell apoptotic cascade is activated when the DNA damage is irreversible
doi:10.1197/j.jht.2004.02.009 [6] Schmid AB, Fundaun J, Tampin B
US$ 22.64
US$ 24.07
US$ 21.39
US$ 24.92
